Here are four notes:
1. Analysts expect the company’s EPS growth to fall 14.29 percent.
2. During the last trading session, NuVasive stock increased 1.73 percent.
3. The shares have underperformed the S&P 500 by 2.05 percent.
4. NuVasive shares have decreased 13.06 percent since July 2015.
More articles on devices:
Dr. Rick Pospisil to offer carpal tunnel procedures — 5 points
NuVasive establishes new 52-week low: 4 points
Medtronic launches Valleylab FT10 energy platform: 4 highlights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
